Pipeline updates are highly-awaited events in the
pharma/biotech sector as they play an important role in deciding
whether to invest in a particular company or not. These updates
provide information on experimental drugs and sometimes give an
insight on the commercial potential of the candidate once it is
successfully developed and commercialized.
BAYER A G -ADR (BAYRY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
Several companies submit abstracts on their drugs at scientific
meetings where the data can be showcased.
The World Diabetes Congress 2013, held in Australia, has provided
) to present data on their diabetes portfolio. Last week, Sanofi
shared data on Lyxumia (lixisenatide) from a 24-week phase III
study (n = 451).
The study evaluated the use of Lyxumia either before breakfast or
the main meal of the day in patients suffering from type II
diabetes, who have not derived sufficient benefit from metformin.
It was found that at either time of administration, Lyxumia was
effective in lowering blood sugar levels. Comparable mean HbA1c
reduction, an indicator of glucose level in the blood, was
observed in both arms of the study - before breakfast (0.74%) and
the main meal (0.65%). Additionally, mean change in body weight
was also similar, in the main meal group (2.6 kg) and in the
breakfast group (2.8 kg). Flexibility in timing of administration
of the drug will be convenient for patients.
Lyxumia is currently available in several countries in Europe
(including the UK, Germany, Spain), Japan and Mexico for use in
combination with oral glucose-lowering medicines and/or basal
insulin when these, in combination with lifestyle management, do
not provide adequate glycemic control. In the third quarter of
2013, the drug generated sales of approximately €3 million.
However, Lyxumia is yet to be approved in the U.S. where Sanofi
withdrew its new drug application for the drug in Sep 2013.
Sanofi intends to resubmit the NDA in 2015, following the
completion of the ELIXA cardiovascular (CV) outcomes study.
Sanofi had in-licensed Lyxumia from Zealand Pharma.
Although Sanofi holds a strong position in the diabetes market,
we note that the market is highly crowded with players like
Eli Lilly and Co.
Sanofi carries a Zacks Rank #3 (Hold). Some better-ranked stocks
). The stock carries a Zacks Rank #2 (Buy).